Adult T-cell leukemia/lymphoma (ATL) is an aggressive lymphoproliferative disease caused by human T-cell leukemia virus type 1 (HTLV-1). Multi-agent chemotherapy can reduce ATL cells but frequently allows relapses within a short period of time.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) following chemotherapy is now a standard therapy for ATL in Japan as it can achieve long-term remission in approximately one-third of recipient ATL patients; however, it also has a risk of treatment-related mortality. Allo-HSCT often induces HTLV-1 Tax-specific cytotoxic T cells (CTL) as well as graft-versus-host (GVH) response in ATL patients. This observation led to development of a new therapeutic vaccine to activate Tax-specific CTL, anticipating anti-ATL effects without GVH response. The newly developed Tax-DC vaccine consists of autologous dendritic cells pulsed with Tax peptides corresponding to CTL epitopes that have been identified in post-allo-HSCT ATL patients. In a pilot study of Tax-DC therapy in three ATL patients after various initial therapies, two patients survived for more than 4 years after vaccination without severe adverse effects (UMIN000011423). The Tax-DC vaccine is currently under phase I trial, showing a promising clinical outcome so far. These findings indicate the importance of patients' own HTLV-1-specific T-cell responses in maintaining remission and provide a new approach to anti-ATL immunotherapy targeting Tax. Although Tax-targeted vaccination is ineffective against Tax-negative ATL cells, it can be a safe alternative maintenance therapy for Tax-positive ATL and may be further applicable for treatment of indolent ATL or even prophylaxis of ATL development among HTLV-1-carriers.
sIL-2Rα in the serum and indicated the OS at 4 years to be 26.2%, 55 .6% and 77.6% for low, intermediate and high-risk groups, respectively. Despite the presence of obvious hematological abnormalities, "watchful waiting" is usually recommended for indolent ATL, unless unfavorable prognostic factors appear, including elevated lactate dehydrogenase or blood urea nitrogen, or decreased albumin levels. 2 For acute-and lymphoma-type ATL, multi-agent chemotherapy and subsequent allo-HSCT are commonly used in Japan, achieving long-term remission in one-third of ATL cases. 4, 5 Recently, mogamulizumab 6 and lenalidomide 7 have also become available for acute-and lymphoma-type ATL. However, neither of these drugs are approved for indolent ATL yet. Combined IFN-α/AZT therapy is widely used for ATL in other countries and is reported to be effective, especially for indolent ATL.
8,9
We recently developed a new therapeutic vaccine, Tax-DC, to activate HTLV-1 Tax-specific cytotoxic T cells (CTL), consisting of Tax peptide-pulsed autologous DC. 10 This was based on the experimental findings that Tax-specific CTL showed anti-tumor effects in animal models of HTLV-1-infected tumors and the clinical observation that Tax-specific CTL were activated in ATL patients after allo-HSCT. 11 A clinical study of the Tax-DC vaccine in a small number of ATL patients after various chemotherapy regimens suggests its potential role in achieving long-term remission. 10 These findings indicate the importance of patients' own immunity in maintenance of remission.
In this review, we focus on the Tax-targeted vaccine therapy, which provides a new approach to ATL therapy, which could be extended for treatment of indolent ATL or even ATL prophylaxis. We also discuss the mechanisms of immunosuppression, a key issue underlying ATL development, which is another important target for induction of anti-tumor immunity in therapeutic and prophylactic strategies against ATL.
| CURRENTLY AVAIL AB LE ATL THER APIE S
For acute-and lymphoma-type ATL, multi-agent chemotherapy, mogamulizumab, lenalidomide and HSCT are currently available in Japan. The mechanisms of anti-ATL effects and influences on the host immunity of these therapies are summarized in Table 1 .
For the last few decades since the discovery of ATL, various regimens of chemotherapy have been tried for ATL with limited success. The median survival time of ATL patients treated with the latest regimen of multi-agent chemotherapy (VCAP-AMP-VECP) was 12.7 months. 12 Chemotherapy is effective in reducing ATL cells but allows frequent relapses.
Mogamulizumab is a humanized anti-CCR4 antibody that reduces ATL cells mainly through antibody-dependent cellular cytotoxicity by NK cells. 13 Because Treg partly express CCR4, mogamulizumab also reduces Treg, which is of potential benefit for reducing immunosuppression. 14 However, this is presumably a cause of the trend of severe adverse effects of HSCT in some patients who were previously treated with mogamulizumab.
15
Median survival time of mogamulizumab for relapsed ATL patients was 13.7 months.
6
Lenalidomide has been used for multiple myeloma and was recently approved for ATL in Japan. Lenalidomide exerts its anti-tumor and immunomodulatory effects through binding with cereblon. Japan. The reported 5-year OS rates for IFN-α/AZT were 28%, 0% and 100% for acute, lymphoma and indolent types of ATL, respectively. 19 Mechanisms of anti-ATL effects of IFN-α/AZT therapy include suppression of Tax expression and activation of the p53 pathway. 20 However, IFN-α/AZT therapy frequently allows relapse of ATL after cessation of treatment. 21 To overcome the frequent relapses in aggressive types of ATL, allo-HSCT has been used for ATL patients combined with multi-agent chemotherapy in Japan, 4 although early attempts at autologous HSCT in ATL patients were unsuccessful. 22 In a retrospective analysis of 386 ATL cases treated with allo-HSCT, the 3-year OS was 33%, while allo-HSCT also caused treatmentrelated mortality in a similar number of patients. 5 The reduced intensity conditioning regimens of allo-HSCT slightly improved the treatment-related mortality, 23 while the survival curve still rapidly declined in the first 1-2 years, before reaching a plateau. 24 
| AC TIVATI ON OF TA X-S PECIFI C C TL AF TER ALLO -H SC T
In allo-HSCT, the hematopoietic system of a recipient ATL patient is replaced with donor-derived hematopoietic cells. GVH response is the main anti-tumor mechanism of allo-HSCT, where the GVH responder T cells eliminate residual ATL cells together with other recipient cells. However, GVH response also causes GVH disease that can be fatal. Therefore, immunosuppressants are required for some time after allo-HSCT. After hematopoietic chimerism is established, the newly constituted system of T-cell tolerance begins to control the GVH response. In addition, activation of CD8 + HTLV-1 Tax-specific CTL is often observed in ATL patients following allo-HSCT, especially after removal of immunosuppressants. 
| ATL REL APS E AND ITS PRE VENTI ON BY ALLO -H SC T
It is unclear why ATL relapses so frequently in a short period of time after chemotherapy. This may be related to the fact that HTLV-1- This scenario is consistent with previous reports that the dominant ATL clones sometimes change during the disease course and also between tissues.
30,31
In contrast, allo-HSCT eradicates recipient-derived cells irrespec- 
| TA X-TARG E TED THER APEUTI C VACCI N E
The findings in ATL patients after allo-HSCT led to the hypothesis that a vaccine to activate Tax-specific CTL may induce long-term remission in ATL patients without GVHD. Our previous study using a rat model indicated that a vaccine using Tax peptide corresponding to the major epitope of CD8 + Tax-specific CTL induced tumor eradication, when appropriate adjuvant was used. 32 To overcome the severe immunosuppression in ATL patients, we chose autologous monocyte-derived DC matured in vitro as an adjuvant for anti-ATL vaccine. 33 These DC were pulsed with Tax peptides corresponding to the major Tax-specific CTL epitopes previously identified in post-HSCT ATL patients (Figure 2 ).
In a small pilot study, the Tax-DC vaccine was administrated s.c. to three ATL patients in stable condition after initial therapies, but who could not receive allo-HSCT for various reasons. 10 After three inoculations with Tax-DC vaccine, Tax-specific CTL were clearly activated in these patients without severe adverse effects. A long-term clinical follow up found that two of three patients survived for more than to be confirmed by a phase II study, the clinical outcomes of these studies indicate that Tax-specific CTL may contribute considerably to maintenance of remission in ATL patients unless Tax-negative ATL clones emerge at relapse. Three patients with acute ATL were enrolled in the pilot study of Tax-DC vaccine at least 1 mo after previous therapies. CTL function by blockade of PD-1/PD-L1 interaction has been reported. 47 PD-L1 is expressed on ATL cells in 7.4% of ATL cases, 48 and alteration of this gene is frequently found in ATL cells. 49 
| TA X E XPRE SS I ON IN ATL CELL S IN V I VO

| TA X-TARG E TED VACCINE A S A P OTENTIAL E ARLY AND/OR PROPHYL AC TIC THER APY
There is no approved therapy for indolent ATL in Japan. Intensive chemotherapy may not be suitable, as it induces immunosuppression. Chemotherapy is one of the factors for worse prognosis in indolent ATL. 54 IFN-α/AZT is effective for indolent ATL, but requires continuous medication, as cessation of IFN-α/AZT allows relapse. 21 Because Tax-silencing is presumed to be less frequent in earlier stages, a Tax-targeting vaccine may be a good candidate to treat indolent ATL.
It is also worth considering the use of Tax Although it has shown promise, the prototype Tax 
| CON CLUS ION
In conclusion, the Tax-DC vaccine study provides a new concept in ATL therapy that invokes the patient's own immunity, particularly Taxspecific CTL, following only a short course of vaccination. These CTL F I G U R E 4 Potential position of the Tax-DC vaccine in currently available adult T-cell leukemia/lymphoma (ATL) therapies. Among currently available anti-ATL therapies, allogeneic hematopoietic stem cell transplantation (allo-HSCT) invokes host immunity against ATL, while other therapies reduce ATL cells. Mogamulizumab and lenalidomide also have immunomodulatory effects to support T-cell immunity without specificity. Tax-DC vaccine activates Tax-specific cytotoxic T cells (CTL) to maintain remission when used after other initial therapies. It may also be an appropriate therapy for earlier stages of ATL and potentially contribute to prophylactic strategies against ATL in the future, because of its limited toxicity. Approved (solid line) and not-approved (dotted line) usages in Japan are shown. HAM-TSP, HTLV-1-associated myelopathy/tropical spastic paraparesis; IFN-α/AZT, interferon-α and azidothymidine; HTLV-1, human T-cell leukemia virus type 1 contribute to long-lasting remission by continuously surveying HTLV-1-infected cells, although the CTL become ineffective when Taxnegative ATL cells proliferate in advanced stages. In addition, because of the limited toxicity, the timing of the Tax-targeted vaccine therapy may potentially be shifted to earlier stages of ATL (Figure 4 ), which may contribute to prophylactic strategies against ATL in the future.
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